Repligen (NASDAQ:RGEN) Shares Gap Up to $123.15

Repligen Co. (NASDAQ:RGEN) gapped up before the market opened on Wednesday . The stock had previously closed at $123.15, but opened at $126.74. Repligen shares last traded at $127.75, with a volume of 184,009 shares.

Analyst Ratings Changes

A number of analysts have recently issued reports on RGEN shares. JPMorgan Chase & Co. reduced their target price on Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a report on Thursday, May 2nd. Guggenheim assumed coverage on Repligen in a research report on Tuesday, June 18th. They set a “neutral” rating for the company. Finally, Deutsche Bank Aktiengesellschaft upgraded Repligen from a “hold” rating to a “buy” rating and dropped their target price for the company from $180.00 to $155.00 in a report on Wednesday. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $193.00.

Repligen Stock Down 0.3 %

The stock has a market cap of $7.07 billion, a price-to-earnings ratio of 506.38, a P/E/G ratio of 4.24 and a beta of 1.04. The business has a fifty day moving average of $152.33 and a 200 day moving average of $174.10. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.35 and a quick ratio of 5.24.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.01). Repligen had a return on equity of 3.95% and a net margin of 2.44%. The business had revenue of $151.31 million for the quarter, compared to analyst estimates of $150.06 million. During the same quarter last year, the company earned $0.64 EPS. The business’s revenue for the quarter was down 17.1% compared to the same quarter last year. On average, equities analysts predict that Repligen Co. will post 1.46 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Anthony Hunt sold 20,072 shares of the stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total transaction of $3,377,314.72. Following the transaction, the chief executive officer now owns 163,177 shares of the company’s stock, valued at approximately $27,456,162.02. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, Director Martin D. Madaus bought 1,615 shares of the business’s stock in a transaction on Friday, June 14th. The stock was purchased at an average price of $124.94 per share, with a total value of $201,778.10. Following the transaction, the director now directly owns 4,613 shares in the company, valued at $576,348.22. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Anthony Hunt sold 20,072 shares of the firm’s stock in a transaction dated Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total value of $3,377,314.72. Following the completion of the sale, the chief executive officer now directly owns 163,177 shares in the company, valued at $27,456,162.02. The disclosure for this sale can be found here. Insiders own 1.20% of the company’s stock.

Institutional Trading of Repligen

Hedge funds have recently added to or reduced their stakes in the business. CWM LLC lifted its holdings in shares of Repligen by 19.9% during the first quarter. CWM LLC now owns 361 shares of the biotechnology company’s stock worth $66,000 after buying an additional 60 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in Repligen by 0.3% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 22,178 shares of the biotechnology company’s stock worth $3,805,000 after acquiring an additional 62 shares during the period. abrdn plc raised its stake in Repligen by 1.4% during the 4th quarter. abrdn plc now owns 5,192 shares of the biotechnology company’s stock valued at $934,000 after purchasing an additional 71 shares during the last quarter. Commerce Bank grew its position in Repligen by 4.5% in the 4th quarter. Commerce Bank now owns 1,683 shares of the biotechnology company’s stock worth $303,000 after purchasing an additional 72 shares during the last quarter. Finally, Quadrant Capital Group LLC increased its holdings in shares of Repligen by 15.1% during the 4th quarter. Quadrant Capital Group LLC now owns 649 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 85 shares during the period. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.